Results 171 to 180 of about 2,198,221 (190)

Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins

Mycopathologia, 2016
The naturally high minimum inhibitory concentration exhibited by echinocandins against Candida parapsilosis has been known since the first introduction of these antifungal agents. Despite this awareness, clinical failures have not been reported; consequently, the resistance of C. parapsilosis to echinocandins remains unexplored.
Francieli, Chassot, Tarcieli Pozzebon, Venturini, Fernanda Baldissera, Piasentin, Luana, Rossato, Adriana, Fiorini, Terezinha Inez Estivalet, Svidzinski, Sydney Hartz, Alves   +6 more
openaire   +2 more sources

Echinocandin resistance in human pathogenic fungi

Expert Review of Anti-infective Therapy, 2012
Immunocompromised patients are at risk of developing invasive fungal infections that have mortality rates ranging from 30 to 90%.
openaire   +2 more sources

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species

Diagnostic Microbiology and Infectious Disease, 2015
MGCD290, a Hos2 fungal histone deacetylase inhibitor, showed modest activity when tested alone (MIC range, 0.12-4 μg/mL; MIC50/90, 0.5/4 μg/mL) against Candida glabrata (n=15; 14 fks mutants; 5 also fluconazole resistant), Candida albicans (8 fks mutants; 2 also fluconazole resistant), Candida tropicalis (4 fks mutants), and Candida krusei (3 fks ...
M A, Pfaller, P R, Rhomberg, S A, Messer, M, Castanheira   +3 more
openaire   +2 more sources

Echinocandin-Resistant Candida: Molecular Methods and Phenotypes

Current Fungal Infection Reports, 2011
We now have a decade of experience with echinocandin drugs. Large-scale epidemiologic antifungal surveillance studies have demonstrated that caspofungin, micafungin, and anidulafungin retain high potency on clinical isolates of Candida, and resistance remains relatively low.
openaire   +1 more source

Echinocandin-resistant Candida albicans: A case report from Japan

Journal of Infection and Chemotherapy
Echinocandin-resistant Candida albicans (C. albicans) is a rare but increasing global concern. In Japan, at least three cases had been confirmed by the end of 2015. Mutations in FKS cause echinocandin resistance in Candida species, which is primarily driven by previous echinocandin antifungal use. C.
Sayaka Hikida, Yutaro Akiyama, Masahiro Ishikane, Hiroshi Shimazu, Ryo Nasu, Takayuki Shinohara, Minoru Nagi, Rei Shirai, Makiko Onakado, Nobuko Nakayama, Yoshitsugu Miyazaki, Akira Hangaishi, Norio Ohmagari   +12 more
openaire   +2 more sources

isolates carrying mutations outside hotspot regions confer high echinocandin tolerance and facilitate the development of echinocandin resistance

International Journal of Antimicrobial Agents, 2023
Michael K Mansour, Geraldine Butler, Ulrike Binder   +2 more
exaly  

Whole genome sequencing analysis demonstrates therapy-induced echinocandin resistance in Candida auris isolates

Mycoses, 2023
Theun de Groot, Eelco Fj Meijer, Mohammad Asadzadeh   +2 more
exaly  

Echinocandin resistance in sensu stricto: Role of alterations in , and gene expression

Journal of Global Antimicrobial Resistance, 2020
Mohammad T. Hedayati, Maryam Moazeni, Iman Haghani   +2 more
exaly  

Emergence of Echinocandin Resistance Due to a Point Mutation in the fks1 Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis.

Antimicrobial Agents and Chemotherapy, 2017
David W. Denning, David S Perlin, Cristina Jimenez-Ortigosa   +2 more
exaly  

Echinocandin Resistance

2017
openaire   +1 more source